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Abstract

Background: While evidence for white matter and astrocytic abnormalities exist in autism, a detailed
investigation of astrocytes has not been conducted. Such an investigation is further warranted by an increasing
role for neuroinflammation in autism pathogenesis, with astrocytes being key players in this process. We
present the first study of astrocyte density and morphology within the white matter of the dorsolateral
prefrontal cortex (DLPFC) in individuals with autism.
Methods: DLPFC formalin-fixed sections containing white matter from individuals with autism (n = 8, age =
4-51 years) and age-matched controls (n = 7, age = 4-46 years) were immunostained for glial fibrillary acidic
protein (GFAP). Density of astrocytes and other glia were estimated via the optical fractionator, astrocyte
somal size estimated via the nucleator, and astrocyte process length via the spaceballs probe.
Results: We found no evidence for alteration in astrocyte density within DLPFC white matter of individuals
with autism versus controls, together with no differences in astrocyte somal size and process length.
Conclusion: Our results suggest that astrocyte abnormalities within the white matter in the DLPFC in autism
may be less pronounced than previously thought. However, astrocytic dysregulation may still exist in autism,
even in the absence of gross morphological changes. Our lack of evidence for astrocyte abnormalities could
have been confounded to an extent by having a small sample size and wide age range, with pathological
features potentially restricted to early stages of autism. Nonetheless, future investigations would benefit from
assessing functional markers of astrocytes in light of the underlying pathophysiology of autism.
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Abstract
Background: While evidence for white matter and astrocytic abnormalities exist in autism, a detailed investigation
of astrocytes has not been conducted. Such an investigation is further warranted by an increasing role for
neuroinflammation in autism pathogenesis, with astrocytes being key players in this process. We present the
first study of astrocyte density and morphology within the white matter of the dorsolateral prefrontal cortex
(DLPFC) in individuals with autism.
Methods: DLPFC formalin-fixed sections containing white matter from individuals with autism (n = 8, age = 4–51 years)
and age-matched controls (n = 7, age = 4–46 years) were immunostained for glial fibrillary acidic protein (GFAP). Density
of astrocytes and other glia were estimated via the optical fractionator, astrocyte somal size estimated via the nucleator,
and astrocyte process length via the spaceballs probe.
Results: We found no evidence for alteration in astrocyte density within DLPFC white matter of individuals with autism
versus controls, together with no differences in astrocyte somal size and process length.
Conclusion: Our results suggest that astrocyte abnormalities within the white matter in the DLPFC in autism may be less
pronounced than previously thought. However, astrocytic dysregulation may still exist in autism, even in the absence of
gross morphological changes. Our lack of evidence for astrocyte abnormalities could have been confounded to an extent
by having a small sample size and wide age range, with pathological features potentially restricted to early stages of
autism. Nonetheless, future investigations would benefit from assessing functional markers of astrocytes in light of the
underlying pathophysiology of autism.
Keywords: Astrocytes, Glia, Autism, Dorsolateral prefrontal cortex (DLPFC), Cell density, White matter

Background
Autism is a highly complex and heritable neurodevelopmental disorder with prevalence rates soaring from
1 in 5000 children in the 1970s [1] to 1 in 132 global
prevalence reported in recent years [2]. The majority of
post-mortem brain studies in autism have focused on
uncovering neuronal abnormalities; however, recent
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evidence has demonstrated alterations in both microglial and astrocytic markers within the autistic brain
[3]. Microglia and astrocytes are known to have crucial
roles in neurodevelopment, including regulation of synapse formation as well as neuroinflammatory and immune pathways. As both synaptogenesis disruption and
neuroinflammation are reported in autism, a role for
microglial and astrocyte involvement in the pathophysiology of autism has begun to receive an increasing
amount of attention [3–5].
Astrocytes represent the most abundant glia cell type
in the brain, and in their mature state, form tripartite
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synapses together with presynaptic and postsynaptic
neurons in a three-way interaction to regulate neuronal
signaling via neurotransmitter/gliotransmitter receptors
and ion channels at the level of a single synapse or a
neuronal network [3, 6–8]. Astrocytes have also been
shown to play a critical role in oligodendrocyte survival
and maturation, including influencing the ability of oligodendrocytes to myelinate axons [9, 10]. In addition,
glial fibrillary acidic protein (GFAP), a major structural
component of astrocytes, has been shown to be necessary for the integrity of CNS white matter as well as
long-term maintenance of myelination [11]. This is of
interest given post-mortem studies have revealed axonal
thinning within the white matter in individuals with autism as well as reduced myelin thickness in the anterior
cingulate cortex (ACC) and prefrontal cortex (PFC) [12].
While neuroimaging studies have shown accelerated maturation of white matter within the frontal cortex [13, 14],
increased gray and white matter volume in the frontal and
temporal regions [15–18], as well as hyper-connectivity in
prefrontal, amygdala, and temporal regions [18, 19]. Along
with the ACC, the dorsolateral prefrontal cortex (DLPFC)
is responsible for higher level executive functioning, including attention, emotional processing, learning and
memory, domains that are impaired in individuals with
autism [20]. This is evidenced by several studies reporting
impairments in individuals with autism compared to controls when performing tasks known to be mediated by the
DLPFC, including poor performance in the Wisconsin
Card Sorting Test (WCST), as well as decreased functional activity as measured by magnetic resonance spectroscopy (MRS) and functional magnetic resonance
imaging (fMRI) [21–23].
Evidence for astrocyte dysfunction have also come
from a post-mortem brain investigation in autism demonstrating increased mRNA levels of GFAP as well as
the excitatory amino acid transporter 1 (EAAT1) via
microarray profiling within the cerebellum, with upregulation confirmed at the protein level via western blotting
[24]. Subsequently, Vargas et al. demonstrated increased
GFAP in the cerebellum, middle frontal gyrus, and ACC
within individuals with autism compared to controls
[25]. This was followed by Laurence and Fatemi’s results,
also demonstrating increased protein levels of GFAP in
the superior frontal, parietal and cerebellar cortex in autism [26]. Further support for prefrontal and cerebellar
changes were demonstrated by a quantitative real-time
polymerase chain reaction (qPCR) investigation showing
increased GFAP expression in both regions in autism
compared to controls [27]. In addition, Crawford et al.
demonstrated increased GFAP at the protein level via
western blotting within the white matter of the anterior
cingulate gyrus, but not in the gray matter [28]. In contrast to increased GFAP levels within the brain in
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autism, Morgan et al. demonstrated no difference in
density and size of astrocytes between autism and controls following a stereological study of the amygdala
[29]. Other astrocytic abnormalities have also been observed in the brains of individuals with autism, including
reduced protein levels of aquaporin 4 (AQP4) within the
cerebellum together with elevated connexin 43 (CNX43)
seen in the superior frontal cortex [30].
Astrocytes are known to be intimately involved in the
inflammatory response within the CNS [31], with growing evidence implicating neuroinflammation in the
pathophysiology of autism, especially via dysregulation
of neurogenesis and neuronal physiology related to activation of microglia and astrocytes [5, 32, 33]. Astrocyte
activation in autism has been suggested to occur due to
observations of astrogliosis in the cerebellar white matter and subcortical white matter within the frontal lobe
[25–27]. Given that astrocytes are known to be involved
in neurodevelopment, potential changes in their activation state and/or functioning due to inflammation during development might have consequences for disrupted
connectivity and neuropathological changes in autism
[34]. Activation of astrocytes and the subsequent proinflammatory cytokines release, including interleukin 6
(IL-6), tumor necrosis factor alpha (TNFα), and interleukin 1B (IL-1B), has also been observed in autism within
the brain as well as peripherally in the cerebrospinal
fluid [25, 35].
Given the growing body of evidence for astrocytic involvement in autism, and their known functioning in
maintaining myelin, together with disruptions in myelin
integrity seen within the brain of individuals with autism, a more detailed investigation of astrocytic neuropathology within the white matter is warranted. The aim
of this investigation was to assess astrocyte density and
morphology within the white matter of the DLPFC in
autism compared to age- and gender-matched controls
using GFAP as a cellular astrocyte marker. This was
achieved using the optical fractionator, nucleator, and
spaceballs probes to investigate density, somal size, and
overall process length respectively.

Methods
Brain tissue

Formalin-fixed DLPFC tissue blocks restricted to BA9
and BA46 from individuals with autism (n = 11) and
controls (n = 10) were provided by the NICHD Brain
and Tissue Bank for Developmental Disorders (NBTBD),
Baltimore, Maryland upon request (University of Melbourne ethics approval ID: 1339835.1). Tissue was
matched as closely as possible for age between autism
(range = 4–51 years) and controls (range = 4–46 years).
Tissue blocks were serially sectioned using a Leica
VT1000s Vibratome (Leica Biosystems, Germany) in
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phosphate-buffered saline (PBS) at 50 μM and stored in
PBS with 0.5% sodium azide at 4 °C. Six samples (3 autism, 3 controls) were excluded from analysis due to poor
tissue morphology following immunohistochemistry,
thereby reducing the number of cases available to 8 autism and 7 controls (Table 1).

grid applied for data collection. Within StereoInvestigator, we utilized the optical fractionator probe to estimate astrocyte and glia density, with simultaneous
application of the nucleator probe for astrocyte somal
size estimation. The spaceballs probe was used to estimate total astrocyte process length. For detailed
methods, please refer to Additional file 1.

Immunohistochemistry

Four sections from each subject were chosen via systematic
random sampling (every 14 sections) spanning the entire
tissue blocks and processed for immunohistochemistry
using a Vectastain ABC Kit (Vector Laboratories, USA)
and a rabbit polyclonal antibody against GFAP (DAKO,
Denmark) [1:4000]. For detailed methods, please refer to
Additional file 1.
Astrocyte density and morphological measurement

All density quantitation was performed using a ×100 oil
immersion objective lens (numerical aperture = 1.4) and
a Nikon Eclipse 80i (Nikon Instruments, Japan) together with StereoInvestigator 11 (MBF Biosciences,
USA) as described previously [33]. A pilot study was
conducted to determine sampling parameters of probes
including disector depth, size of sampling contour, and
numbers of sampling fields in order to achieve coefficient of error (CE) below 0.05 [36]. Three regions of
interest defined by 1 mm × 2 mm (optical fractionator
and nucleator) or 1 mm × 1 mm (spaceballs) were
drawn using ×4 objective lens within the white matter
for each section and systematic random sampling (SRS)

Statistical analysis

All measures were tested for normality using a
Shapiro-Wilk test, with Pearson or Spearman correlations, carried out between our outcome measures, age,
and post-mortem interval (PMI). Any significant correlation at p < 0.05 were considered as covariates during analysis for group differences. A general linear
model was used to test differences between groups for
normally distributed measures while a Mann-Whitney U
test was utilized for non-parametrically distributed
measures.

Results
Identification of adjustment variables

Shapiro-Wilk normality tests demonstrated that nucleator area (p = 0.023) was not normally distributed within
the autism group; however, all other measures including
age, post-mortem interval (PMI), astrocytes density,
negative glia density, total glia density, spaceballs length,
and IOD were normally distributed. No significant correlations were observed (Table 2).

Table 1 Brain tissue demographics
Sample ID

Age

Cause of death

Sex

PMI (h)

Diagnosis

Years

Days

5308

4

182

Skull fractures

M

21

ASD

5144
4899

7

55

Complications from cancer

M

3

ASD

14

126

Drowning

M

9

ASD

5403

16

266

Cardiac arrhythmia

M

35

ASD

4999

20

274

Cardiac arrhythmia

M

14

ASD

5578

35

294

Accident

M

22

ASD

5115

46

135

Complications of pseudomyxoma peritonei

M

29

ASD

5137

51

91

Pneumonia

M

72

ASD

1185

4

258

Drowning

M

17

Control

1500

6

320

Multiple injuries

M

18

Control

917

14

217

Accident/multiple injuries

M

10

Control

1158

16

63

Cardiomegaly

M

15

Control

4916

19

47

Accident/drowning

M

5

Control

4593

33

24

Cardiac arrhythmia

M

8

Control

1936

46

35

Arteriosclerotic cardiovascular disease

M

13

Control

0.938
0.922

Control

0.982

Control

ASD

0.901

0.866

Control

ASD

0.791

0.868

Control

ASD

0.951

0.978

Control

ASD

0.969

0.873

Control

ASD

0.950

0.954

Control

ASD

0.864

0.907

Control

ASD

0.907

7

8

7

8

7

8

7

8

7

8

7

8

7

8

7

8

0.487

0.591

0.970

0.298

0.170

0.023

0.178

0.718

0.949

0.894

0.196

0.715

0.766

0.133

0.374

0.335

Correlation PMI

− 0.206
(p = 0.461)
− 0.517
(p = 0.059)

− 0.681
(p = 0.007)

− 0.392
(p = 0.149)

− 0.289
(p = 0.296)

0.219
(p = 0.433)

0.168
(p = 0.549)

− 0.267
(p = 0.337)

Pearson (r)

− 0.390
(p = 0.150)

− 0.093
(p = 0.742)

Spearman (rho)

0.205
(p = 0.463)

Correlation age

Sig.

Pearson (r)

df

Shapiro-Wilk normality test
Statistic

ASD

General linear model
b
Non-parametric independent sample t test
c
General linear model with covariate “age”

a

IOD (mean)

Spaceballs length (all) (um)

Nucleator (area)

Population (other glia)

Population (astrocyte)

Population (all glia)

PMI (h)

Age

Diagnosis

Table 2 Statistical analysis of normality test, correlation test, and group comparison between autism and control

− 0.118
(p = 0.676)

Spearman (rho)

156.127

143.083

52,176,610.3

51,228,155.8

87.423

92.475

2,234,289.88

2,401,035.25

117,513.34

100,669.51

2,351,803.21

2,401,704.83

12.286

25.625

20.092

24.612

4.809

4.159

7,017,046.63

6,563,846.09

4.870

4.556

132,828.19

124,249.39

9148.48

8557.62

129,883.17

121,494.58

6.065

5.673

6.204

5.803

SE

0.066c

0.923a

0.397b

0.376a

0.202a

0.415a

0.132a

0.604a

p value

Group differences (ASD vs control)
Mean
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Astrocyte and total glial densities

No significant differences in the density of astrocytes
were seen between autism and controls (autism =
10.07 × 104 ± 85.58 × 102, control = 11.75 × 104 ± 91.48 ×
102 (mean ± SEM); p = 0.202, Fig. 1a). In addition, no
group differences were seen for GFAP negative glia (autism = 24.01 × 105 ± 12.42 × 104, control = 23.34 × 105 ±
13.28 × 104 (mean ± SEM); p = 0.376, Fig. 1b), or total
glia (autism = 24.02 × 104 ± 12.15 × 104, control = 23.52 ×
104 ± 12.99 × 104 (mean ± SEM); p = 0.415, Fig. 1c).
Astrocyte somal size and process length

As somal sizes were not normally distributed within the
autism group, we employed a Mann-Whitney U nonparametric test to compare differences between autism and
control groups. No significant difference between autism
and controls were seen for somal area of white matter astrocytes (autism = 92.475 ± 4.56 μm2, control = 87.423 ±
4.87 μm2 (mean ± SEM); p = 0.397, Fig. 2a). Furthermore,
spaceballs analysis showed no significant difference between autism and control group for total length of astrocytes processes in the white matter (autism = 51.23 × 106 ±
65.64 × 105 μm, control = 52.18 × 106 ± 70.17 × 105 μm
(mean ± SEM); p = 0.923, Fig. 2c).

Discussion
This study provides the first investigation of astrocyte
density, morphology, and activation status within the
white matter of the DLPFC in autism. Based on previous
evidence demonstrating increased GFAP within the
brain in autism, we hypothesized that we would observe
an increased density of astrocytes in the white matter of
the DLPFC of individuals with autism. In contrast, our
results demonstrate no difference in the density and cellular morphology of GFAP-positive astrocytes in the
white matter of the DLPFC of autism when compared to
age-matched controls. Our findings are in keeping with
recent studies demonstrating no alteration in astrocyte
number and astrocyte somal size in the amygdala in autism, as well as no increase in GFAP mRNA and protein
in the anterior PFC and ACC [28, 29].
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During severe reactive astrogliosis, a marked increase in
astrocytic size, arborization, GFAP expression, and proliferation are observed [37, 38]. Therefore, the current study investigated the population of GFAP-positive astrocytes along
with other glial cells using StereoInvestigator to obtain an
estimation of astrocyte and glial density, as well as astrocytic somal size and process length. Our results provide
support for no alteration in astrocyte or glial density in the
autism brain, consistent with Morgan et al. reporting no alteration of astrocyte numbers in autism within the amygdala [29]. In addition, our results demonstrated no evidence
for increased astrocytic reactivity within the DLPFC white
matter of individuals with autism compared to controls, as
indicated by no changes in morphology, including cell
somal size and process length. Similar to our findings for
astrocyte somal size, Morgan et al. also found no evidence
for differences in astrocyte somal size between autism and
controls within the amygdala [29].
Our lack of findings for alterations in astrocyte density
and activation status within the DLPFC white matter in
autism represent an absence in gross astrocyte morphological changes in this brain region. However, another possibility is that any astrocyte activation may be present at a
less pronounced level and that our employed strategies for
investigating activation may have not been sensitive
enough to detect such changes. This is in keeping with a
lack of stark neuropathological changes observed in the
autism brain. Yet another possible explanation is that astrocytes measured for our investigation may have resolved
their reactivity and activation status, with morphological
changes potentially taking place much earlier in disease
progression [38]. Given the early developmental nature of
autism and likely heterogeneity in autism pathophysiology,
the latter two possibilities are equally likely to potentially
explain the lack of astrocyte reactivity within our samples.
Our results therefore highlight the need for more sensitive
measures of assessing astrocyte activation as well as potentially assessing temporal and regional changes in astrocyte
activation.
Despite a lack of evidence in our study to suggest activation of astrocytes, their contribution to the pathophysiology of autism might still be very significant.

Fig. 1 Optical fractionator results of ASD and controls. Estimated density of a astrocytes (GFAP positive), b negative glia (GFAP-negative glia), and
c total glia, in the DLPFC of ASD and control subjects
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Fig. 2 Astrocyte morphology estimates. Astrocytes reactivity measures of a cell somal area via nucleator probe, and b cell processes length using
spaceballs probe

Given astrocytes play a central role in regulating the
functions of other cell types in the brain, any loss or gain
of function of astrocytes could have a direct or indirect
effect on brain physiology. Astrocytes contribute to synaptic functioning, especially clearing of glutamate via
transporter EAAT2. A disturbance of this function could
potentially be detrimental to neuronal health and functioning due to excitotoxicity caused by excess glutamate
within the extracellular space [39]. Developmentally, astrocytes contribute to synaptic pruning by actively removing synapses via MEFG10 and MERTK pathways
[40], or by tagging synapses for elimination by microglia
via upregulation of C1q protein, loss of this function
could lead to over- or under-pruning of synapses as observed in autism [41]. Within the white matter, disturbance of astrocytic physiology could also lead to
perturbation of myelination, which has also been observed in autism [42, 43]. Therefore, potential functional
alterations in astrocytes due to neuroinflammation and
change in their activation may warrant a more detailed
investigation in an attempt to tease out the mechanistic
roles of astrocytes in the neuropathology of autism.
Due to the limitation of post-mortem brain samples
available, autism studies including the current one are
often limited by sample size. This also contributed to a
relatively large age range within the cohort investigated.
Consequently, our lack of astrocyte abnormalities in the
current study could to a certain extent have been masked
by an age-related effect, whereby abnormalities present in
early developmental stages may be normalized later in life.
This is particularly interesting given age-related cortical
thinning has been reported within the temporal and parietal cortices of autism brain during adolescence and early
adulthood, despite evidence of cortical overgrowth earlier
in life [44]. In addition, findings from several longitudinal
neuroimaging studies also suggest that brain abnormalities
such as overgrowth is pronounced within the first few
years of life and subsequently found to normalize towards
controls during aging [45–47]. Furthermore, it is not

uncommon for individuals with autism to have comorbid
neurological disorders such as epilepsy, which may additionally represent a confounding factor, with potential
brain changes due to an underlying neurodegenerative
disease. With regard to epilepsy, this would be particularly
pertinent for our investigation as individuals with epilepsy
are known to have increased astrocyte numbers and activation [48].
For this study, we employed a strict protocol of sampling whereby we ensured the CE for all cases was below
0.05, in attempt to increase our precision in estimating
density, size, and process length measurements. As the
spaceballs probe was used to estimate all astrocyte processes present within the ROI regardless of the presence
of the cell body, our results reflect more global increases
in astrocyte length as opposed to arborization characteristics of individual astrocytes. Nevertheless, our data
provides a reliable 3D estimate of overall length of astrocyte processes as a measure of potential astrocyte activation. Future studies may benefit from investigating an
extended suite of astrocyte markers, including aldehyde
dehydrogenase 1 family member L1 (ALDH1L1), glutamate synthetase (GS), and S100 calcium-binding protein B (S100B), to obtain a more complete perspective
on structural and functional astrocyte abnormalities in
the autism brain.

Conclusions
In conclusion, our results suggest that gross morphological
changes in astrocyte density and activation status are not
present in the DLPFC white matter. This could suggest a
lack of astrogliosis, but does not rule out astrocytic abnormalities, that may be present in the absence of gross morphological changes. In addition, regional differences in the
reactivity of astrocytes in the brain in autism may also be
present and should be considered. Further post-mortem investigations within the autism brain should be aimed at
assessing astrocyte abnormalities utilizing more functional
markers of astrocytes to further understand the role that
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astrocytes play in the pathophysiology of autism and their
impact on other cell types in the brain including neurons,
microglia, and oligodendrocytes, with these cells also likely
contributing to the underlying etiology of the disorder.
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